Biofrontera Inc

NASDAQ:BFRI   3:03:23 PM EDT
0.93
-0.05 (-5.11%)
Products, Regulatory

Biofrontera To Launch Phase 3 Clinical Study Evaluating Ameluz®-Pdt For The Treatment Of Actinic Keratosis On The Extremities, Neck And Trunk

Published: 11/21/2022 14:47 GMT
Biofrontera Inc (BFRI) - Biofrontera to Launch Phase 3 Clinical Study Evaluating Ameluz®-pdt for the Treatment of Actinic Keratosis on the Extremities, Neck and Trunk.
Biofrontera Inc - Initially 11 Clinical Trial Sites in U.S. Will Participate.
Biofrontera Inc - Will Enroll Approximately 165 Patients Stratified by Body Region.
Biofrontera Inc - Study is Being Managed by Biofrontera Bioscience Gmbh.